Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight

The Parkinson's disease market is expected to grow steadily, driven by the recent approval of AbbVie's JUVMO along with the rising prevalence of the disease, particularly among the aging population. Increasing disease awareness, improved diagnosis, and advances in symptomatic and disease-management approaches. The development of novel therapies such as bemdaneprocel (BlueRock Therapeutics/Bayer), solengepras (Cerevance), buntanetap (Annovis Bio), prasinezumab (Roche/Prothena), and others is further strengthening the market growth.

LAS VEGAS, Oct. 6, 2026 /PRNewswire/ -- Recently published Parkinson's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Parkinson's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Parkinson's Disease Market Summary

• The total market size of Parkinson's disease in the 7MM was around USD 8 billion in 2025, which is expected to grow at a significant CAGR, reaching a notable value by 2036.
• The United States accounted for the largest Parkinson's disease treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• The total diagnosed prevalent cases of Parkinson's disease in the 7MM were found to be approximately 3 million in 2025, which are expected to increase by 2036.
• Leading Parkinson's disease companies, such as Mitsubishi Tanabe Pharma (NeuroDerm), BlueRock Therapeutics, Bayer, Cerevance, Annovis Bio, Roche, Protherna, AC Immune, Gain Therapeutics, Biohaven, MeiraGTx, and others, are developing new Parkinson's disease treatment drugs that can be available in the Parkinson's disease market in the coming years. 
• The promising Parkinson's disease therapies in clinical trials include ND0612 (Levodopa/Carbidopa), Bemdaneprocel, Solengepras, Buntanetap, Prasinezumab, ACI-7104, Rexaceract (GT-02287), BHV-8000, AAV-GAD, and others.

Find out is there a cure for Parkinson's disease @ https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

Key Factors Driving the Growth of the Parkinson's Disease Market 

• Rising Prevalence of Parkinson's Disease: The growing global burden of Parkinson's disease, particularly among aging populations, is increasing the demand for effective diagnosis and treatment. Longer life expectancy and the rising prevalence of age-related neurological disorders are contributing to market expansion.
• Growing Adoption of Advanced Therapies: Increasing use of advanced treatment options, including deep brain stimulation, continuous drug-delivery systems, and device-aided therapies, is supporting market growth. These approaches offer alternatives for patients with advanced disease or inadequate control with conventional medications.
• Technological Advancements in Drug Delivery: Innovations in continuous infusion, implantable delivery systems, and other targeted drug-delivery technologies are improving treatment consistency and reducing fluctuations in symptom control. These advancements are particularly relevant for patients with advanced Parkinson's disease.
• Growing Demand for Personalized Treatment: Increasing recognition of differences in disease progression and treatment response is encouraging more individualized therapeutic strategies. Biomarker research, digital monitoring, and patient-specific treatment selection may further improve disease management.
• Expansion of the Parkinson's Disease Drug Pipeline: Pharmaceutical companies are investing in novel therapies such as bemdaneprocel (BlueRock Therapeutics/Bayer), solengepras (Cerevance), buntanetap (Annovis Bio), prasinezumab (Roche/Prothena), and others, designed to improve symptom control, address treatment complications, and potentially modify disease progression.

Shikha Bhardwaj, Associate Consultant of Forecasting & Analytics at DelveInsight, said that Novel therapies, including continuous levodopa/carbidopa delivery and cell-based approaches, could improve symptom control, reduce treatment burden, and potentially address underlying neuronal loss. These advances are likely to expand the addressable patient population and drive greater adoption of premium therapies, supporting market growth over the forecast period.

Parkinson's Disease Market Analysis

• Although no curative treatment is currently available for Parkinson's disease, symptom management relies on a combination of pharmacological and nonpharmacological interventions. 
• Pharmacological therapies include levodopa, dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, amantadine, and adenosine A2A receptor antagonists. 
• Nonpharmacological approaches, including physical, occupational, speech, and exercise therapies, are used to improve mobility, daily functioning, and overall quality of life. 
• In patients with advanced disease, additional treatment options include deep brain stimulation and continuous infusion therapies, while complementary approaches may also be used to address specific symptoms.
• Treatment strategies are increasingly tailored according to disease stage, the presence of motor fluctuations and other complications, non-motor manifestations, comorbid conditions, treatment tolerability, and individual patient preferences. 
• The primary objective of pharmacological therapy is to reduce motor symptoms and improve movement-related function in people with Parkinson's disease.
• Levodopa remains the cornerstone and gold-standard therapy for Parkinson's disease. Carbidopa/levodopa is considered the most effective approved monotherapy for controlling motor symptoms and is frequently used as first-line treatment in patients experiencing motor impairment, particularly those with late-onset disease. 
• VYALEV (foslevodopa/foscarbidopa) offers continuous subcutaneous administration of levodopa and has been approved by the US FDA for the treatment of motor fluctuations in adults with advanced Parkinson's disease.
• Recently, in September 2026, the FDA approved tavapadon (JUVMO, AbbVie) tablets for the treatment of Parkinson's disease in adults, making it the first selective D1/D5 receptor agonist approved for the condition. The approval was supported by findings from the TEMPO-3 trial.
• The Parkinson's disease pipeline includes several investigational therapies, such as bemdaneprocel (BlueRock Therapeutics/Bayer), solengepras (Cerevance), buntanetap (Annovis Bio), and prasinezumab (Roche/Prothena), among others.

Parkinson's Disease Competitive Landscape

Some of the Parkinson's disease drugs under development include ND0612 [Levodopa/Carbidopa; Mitsubishi Tanabe Pharma (NeuroDerm)], Bemdaneprocel (BlueRock Therapeutics/Bayer), Solengepras (Cerevance), Buntanetap (Annovis Bio), Prasinezumab (Roche/Protherna), ACI-7104 (AC Immune), Rexaceract (GT-02287; Gain Therapeutics), BHV-8000 (Biohaven), AAV-GAD (MeiraGTx), and others.

Mitsubishi Tanabe Pharma's ND0612 LD/CD is an investigational drug-device combination therapy that delivers liquid levodopa/carbidopa (LD/CD) through continuous subcutaneous infusion over 24 hours per day. The therapy is currently undergoing Phase III clinical development.

BlueRock Therapeutics/Bayer's Bemdaneprocel (BRT-DA01) is an investigational stem cell-derived therapy for Parkinson's disease intended to replace dopamine-producing neurons lost during disease progression. The treatment involves the surgical implantation of dopaminergic neuron precursors into the brain, where they are expected to mature into functional dopamine-producing neurons. Bemdaneprocel received FDA Fast Track designation in 2021 and Regenerative Medicine Advanced Therapy (RMAT) designation in 2024.

Cerevance's Solengepras (CVN424) is an oral, once-daily investigational therapy for Parkinson's disease that targets the GPR6 receptor to regulate the indirect basal ganglia pathway. Designed to complement levodopa without directly modifying dopamine signaling, it may address both motor and non-motor symptoms. By helping rebalance disrupted neural pathways, solengepras could potentially alleviate dyskinesia and other motor complications associated with dopaminergic therapies.

AC Immune's ACI-7104 is an optimized formulation of the company's clinically validated predecessor anti-α-synuclein active immunotherapy. It is designed to elicit a target-specific antibody response against pathological oligomeric α-synuclein, thereby potentially limiting its spread and subsequent neurodegeneration in early Parkinson's disease. The therapy has demonstrated a robust and boostable antibody response, along with evidence of target engagement and an initial signal of clinical efficacy.

The anticipated launch of these emerging therapies are poised to transform the Parkinson's disease market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Parkinson's disease market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about what are the most promising drugs being developed for parkinson's disease @ Parkinson's Disease Clinical Trials

Recent Developments in the Parkinson's Disease Market

• In September 2026, the FDA has approved AbbVie's JUVMO (tavapadon) tablets for the treatment of Parkinson's disease in adults, marking the first approval of a selective D1/D5 receptor agonist for the condition. 
• In September 2026, BioVie announced FDA engagement to align on the Phase III development program for bezisterim in early Parkinson's disease, following positive Phase II SUNRISE-PD results. 
• In August 2026, Zambon announced that the European Commission approved HOPLEDO (levodopa/carbidopa) for the treatment of adults with Parkinson's disease experiencing moderate to severe motor fluctuations. The company expects to begin a phased launch of HOPLEDO across European markets from October 2026.
• In May 2026, Cerevance announced completion of enrollment in the pivotal Phase III ARISE trial, which evaluates 75 mg and 150 mg solengepras versus placebo in patients with Parkinson's disease motor fluctuations.
• In April 2026, Tanabe Pharma announced that the European Commission granted marketing authorization for ONERJI (ND0612), a continuous subcutaneous levodopa/carbidopa infusion, for advanced Parkinson's disease patients experiencing motor fluctuations inadequately controlled with oral anti-Parkinsonian medications.
• In January 2026, Bayer highlighted bemdaneprocel as part of its advancing Parkinson's cell therapy pipeline, with the investigational therapy progressing through pivotal Phase III development in the exPDite-2 trial.

Parkinson's Disease Epidemiology Segmentation

The Parkinson's disease epidemiology section provides insights into the historical and current Parkinson's disease patient pool and forecasted trends for the leading markets. In the UK, among the stage-specific diagnosed prevalent cases of Parkinson's disease, Stage III had the highest cases, with approximately 60,000, whereas Stage V had the lowest cases, 7,200 in 2025, which are expected to increase by 2036.

The Parkinson's disease treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Diagnosed Prevalent Cases of Parkinson's Disease
• Gender-specific Diagnosed Prevalent Cases of Parkinson's Disease
• Age-specific Diagnosed Prevalent Cases of Parkinson's Disease
• Stage-specific Diagnosed Prevalent Cases of Parkinson's Disease
• Diagnosed Prevalent Cases of Psychosis due to Parkinson's Disease
• Diagnosed Prevalent Cases of MCI due to Parkinson's Disease

Scope of the Parkinson's Disease Market Report

• Parkinson's Disease Patient Population Forecast
• Parkinson's Disease Therapeutics Market Size
• Parkinson's Disease Pipeline Analysis
• Parkinson's Disease Market Size and Trends
• Parkinson's Disease Market Opportunity
• Parkinson's Disease Market Unmet Needs
• KOL's Views on Parkinson's Disease
• Parkinson's Disease Market Access and Reimbursement

Download the report to understand the top brands for proactive Parkinson's disease management @ Parkinson's Disease Treatment Market

Table of Contents

Related Reports

Parkinson's Disease Clinical Trial Analysis

Parkinson's Disease Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Parkinson's disease companies, including Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., and others.

Psychosis in Parkinson's and Alzheimer's Disease Market

Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psychosis in Parkinson's and Alzheimer's disease companies, including Sunovion Pharmaceuticals, Karuna Therapeutics, Vanda Pharmaceuticals, Suven Life Sciences, Enterin, Intra-Cellular Therapies, Merck Sharp & Dohme, and others.

Dementia-related Psychosis Market

Dementia-related Psychosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia-related psychosis companies including Acadia Pharmaceuticals, Bristol Myers Squibb, Cognition Therapeutics, Maplight Therapeutics, Johnson & Johnson, AgeneBio, and others.

Alzheimer's Disease Market

Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer's disease companies, including Novo Nordisk, Eli Lilly, Suven Life Sciences, Bristol Myers Squibb, IGC Pharma, T3D Therapeutics, Lexeo Therapeutics, Axsome Therapeutics, Araclon Biotech S.L., Eisai, TauRx Therapeutics, GemVax & KAEL, AC Immune SA, Johnson & Johnson, Longeveron, Vaccinex, Sinaptica Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

SOURCE DelveInsight Business Research, LLP